Advertisement
New Zealand markets closed
  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     
  • NZD/USD

    0.5969
    +0.0006 (+0.10%)
     
  • NZD/EUR

    0.5557
    +0.0002 (+0.03%)
     
  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     
  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     
  • OIL

    79.15
    +0.20 (+0.25%)
     
  • GOLD

    2,310.30
    +0.70 (+0.03%)
     
  • NASDAQ

    17,541.54
    +222.99 (+1.29%)
     
  • FTSE

    8,172.15
    +50.91 (+0.63%)
     
  • Dow Jones

    38,225.66
    +322.37 (+0.85%)
     
  • DAX

    17,896.50
    -35.67 (-0.20%)
     
  • Hang Seng

    18,465.52
    +258.39 (+1.42%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • NZD/JPY

    91.3770
    -0.1980 (-0.22%)
     

We're Keeping An Eye On PainChek's (ASX:PCK) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

So should PainChek (ASX:PCK) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.

Check out our latest analysis for PainChek

Does PainChek Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2022, PainChek had cash of AU$6.1m and no debt. Looking at the last year, the company burnt through AU$7.0m. Therefore, from June 2022 it had roughly 10 months of cash runway. That's quite a short cash runway, indicating the company must either reduce its annual cash burn or replenish its cash. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is PainChek's Cash Burn Changing Over Time?

In our view, PainChek doesn't yet produce significant amounts of operating revenue, since it reported just AU$994k in the last twelve months. Therefore, for the purposes of this analysis we'll focus on how the cash burn is tracking. Over the last year its cash burn actually increased by a very significant 68%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Admittedly, we're a bit cautious of PainChek due to its lack of significant operating revenues. So we'd generally prefer stocks from this list of stocks that have analysts forecasting growth.

How Easily Can PainChek Raise Cash?

Since its cash burn is moving in the wrong direction, PainChek shareholders may wish to think ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

ADVERTISEMENT

PainChek has a market capitalisation of AU$43m and burnt through AU$7.0m last year, which is 16% of the company's market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.

Is PainChek's Cash Burn A Worry?

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought PainChek's cash burn relative to its market cap was relatively promising. Summing up, we think the PainChek's cash burn is a risk, based on the factors we mentioned in this article. Separately, we looked at different risks affecting the company and spotted 5 warning signs for PainChek (of which 3 are significant!) you should know about.

Of course PainChek may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here